Mercado global de tratamento de cãibras noturnas nas pernas – Tendências do setor e previsão para 2029

Análise e dimensão do mercado

As cãibras noturnas nas pernas afetam até 60% dos adultos. A tensão recorrente e dolorosa dos músculos gémeos é comum e pode causar insónia grave. O mecanismo específico é incerto, mas a exaustão muscular e o mau funcionamento dos nervos têm maior probabilidade de induzir cãibras do que distúrbios eletrolíticos ou outros distúrbios. Doença vascular, estenose do canal lombar, cirrose, hemodiálise, gravidez e outros distúrbios médicos estão todos ligados a cãibras noturnas nas pernas. A sacarose de ferro intravenosa, os estrogénios conjugados, o raloxifeno, o naproxeno e a teriparatida são medicamentos intimamente ligados às cãibras nas pernas. A história e o exame físico são geralmente suficientes para distinguir as cãibras noturnas nas pernas de outras perturbações, como a síndrome das pernas inquietas, claudicação, miosite e neuropatia periférica.

A Data Bridge Market Research analisa que o mercado noturno de tratamento de cãibras nas pernas foi avaliado em 364 milhões de dólares em 2021 e deverá atingir os 658,91 milhões de dólares até 2029, registando um CAGR de 7,70% durante o período de previsão de 2022 a 2029. O relatório de mercado com curadoria pela equipa de pesquisa de mercado da Data Bridge inclui análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Definição de mercado

As cãibras nas pernas que ocorrem à noite são caracterizadas por uma sensação de aperto e nó nas pernas. Espasmos dolorosos e involuntários no gémeo ou nas coxas surgem durante a noite. A falta de atividade física, a permanência prolongada ou o encurtamento dos tendões são as causas mais comuns. Podem durar de alguns segundos a alguns minutos. O seu músculo pode ficar dorido durante dias se a cãibra for intensa.

Âmbito do relatório e segmentação de mercado

Dinâmica do mercado de tratamento de cãibras noturnas nas pernas

Motoristas

• Aumento da prevalência de cãibras noturnas nas pernas

Estima-se que a crescente prevalência de cãibras noturnas nas pernas aumente o crescimento do mercado de tratamento de cãibras noturnas nas pernas. As cãibras nas pernas durante a noite são referidas por 50 a 60 por cento dos adultos e cerca de 7% dos jovens. As mulheres têm uma probabilidade ligeiramente maior de as ter e a sua prevalência aumenta com a idade.

• Aumentar o investimento em infraestruturas de saúde

Outro fator significativo que influencia a taxa de crescimento do mercado de tratamento de cãibras noturnas nas pernas é o aumento dos gastos com a saúde que ajuda a melhorar as suas infraestruturas. Além disso, várias organizações governamentais pretendem melhorar a infra-estrutura de saúde aumentando o financiamento e isto influenciará ainda mais a dinâmica do mercado.

• Número crescente da população geriátrica

Estima-se que o aumento da população geriátrica aumente a expansão do mercado durante o período de previsão de 2022-2029. De acordo com a Organização Mundial de Saúde (OMS), a população geriátrica mundial, estimada em mais de 524 milhões em 2010, deverá aumentar para quase 2 mil milhões até 2050. Devido ao seu sistema imunitário comprometido, os geriátricos são mais suscetíveis de contrair doenças.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the nocturnal leg cramps treatment market. Additionally, rise in focuses on management of the nocturnal leg cramps and sedentary lifestyle of people will result in the expansion of nocturnal leg cramps treatment market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the nocturnal leg cramps treatment market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the nocturnal leg cramps treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. Limited primary care services and lack of healthcare infrastructure in developing economies will challenge the nocturnal leg cramps treatment market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This nocturnal leg cramps treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the nocturnal leg cramps treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Nocturnal leg are found in 40% of people over the age of 50 in the general population, grow in frequency with age, have no sex preference, and are linked to sleep disturbances and ill health. Around 7% of children and adolescents have experienced nocturnal leg cramps. The peak age of occurrence in this cohort was 16 to 18 years old, with no instances reported in children under eight. In most cases, nocturnal leg cramps in children are harmless, self-limiting, and uncommon.

Nocturnal leg cramps treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Nocturnal Leg Cramps Treatment Market

Over the projected period, the nocturnal leg cramps treatment market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The nocturnal leg cramps treatment market was hampered by the supply chain slowness.

Global Nocturnal Leg Cramps Treatment Market Scope

The nocturnal leg cramps treatment market is segmented on the basis of drug class, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Calcium Channel Blockers
• Nonsteroidal Anti-Inflammatory (NSAID)
• Others

Diagnosis

• Physical Examination
• Blood Tests
• Others

Dosage Form

• Tablets
• Ointments
• Gels
• Others

Route of Administration

• Oral
• Topical
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Nocturnal Leg Cramps Treatment Market Regional Analysis/Insights

The nocturnal leg cramps treatment market is analysed and market size insights and trends are provided by country, drug class, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the nocturnal leg cramps treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the nocturnal leg cramps treatment market because of the growing prevalence of sedentary lifestyles in this region. Additionally, rising healthcare expenditure along with the availability of treatment options will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to presence of major generic pharmaceuticals companies in this region. Also, the development of healthcare infrastructure will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Nocturnal Leg Cramps Treatment Market Share Analysis

The Nocturnal leg cramps treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to nocturnal leg cramps treatment market.

Some of the major players operating in the nocturnal leg cramps treatment market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France), Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• Boehringer Ingelheim International GmbH. (Germany)
• Apotex Inc. (Canada)
• AstraZeneca (UK)
• Horizon Therapeutics PLC (Ireland)
• Johnson & Johnson (US)
• Bayer AG (Germany)
• Perrigo Company plc (Ireland)
• Tolmar Pharmaceuticals, Inc. (US)
• Reckitt Benckiser Group PLC (Reino Unido)
• Sun Pharmaceutical Industries Ltd. (Índia)
• Assertio Therapeutics, Inc.
• DAIICHI SANKYO COMPANY, LIMITED (Japão)

SKU-53995